PSP Inhibitors
Chemical inhibitors of PSP can exert their inhibitory effects through various biochemical pathways. Lithium chloride, SB216763, and indirubin-3'-monoxime share a common mechanism of action by targeting and inhibiting glycogen synthase kinase-3 (GSK-3). This kinase is known to phosphorylate PSP, leading to its functional inactivation. By inhibiting GSK-3, these chemicals ensure that PSP remains in a dephosphorylated, active state within the cell. Similarly, kenpaullone serves as a dual inhibitor of both GSK-3 and cyclin-dependent kinases (CDKs), which may also target PSP for phosphorylation. The inhibition of these kinases by kenpaullone consequently prevents the phosphorylation of PSP, thereby sustaining its activity. Additionally, paullones and roscovitine, primarily known as CDK inhibitors, can also maintain the activity of PSP by preventing its phosphorylation through the inhibition of CDKs that are capable of modifying PSP.
Furthermore, chemicals like SP600125 and LY294002 disrupt other signaling pathways that intersect with PSP activity. SP600125 inhibits the c-Jun N-terminal kinase (JNK), which can phosphorylate PSP directly or indirectly affect its activity, leading to inhibition. LY294002, as a PI3K inhibitor, blocks the PI3K-Akt signaling pathway, which may activate kinases involved in PSP's phosphorylation. Rapamycin and wortmannin act similarly by inhibiting the mTOR and PI3K pathways, respectively. The inhibition of these pathways by rapamycin and wortmannin prevents the activation of downstream kinases that could phosphorylate and inactivate PSP. Lastly, PD98059 and U0126, both MEK inhibitors, disrupt the MAPK/ERK pathway, which is another potential route for the phosphorylation and inactivation of PSP.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride can inhibit glycogen synthase kinase-3 (GSK-3), a kinase that might phosphorylate PSP, leading to its functional inactivation. Inhibition of GSK-3 by lithium chloride would thus maintain PSP in a dephosphorylated, active state. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763 is another GSK-3 inhibitor. By inhibiting GSK-3, SB216763 can prevent the phosphorylation and subsequent inactivation of PSP, ensuring its functional activity remains unimpaired. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
As a GSK-3 inhibitor, indirubin-3'-monoxime can inhibit the phosphorylation of PSP by GSK-3, allowing PSP to remain active and functional within cellular signaling pathways. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a CDK inhibitor that may inhibit the CDK mediated phosphorylation of PSP, thereby preventing its inactivation and ensuring its continued activity in the cell. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $60.00 $150.00 $226.00 $495.00 | 1 | |
Kenpaullone, another inhibitor of GSK-3 as well as CDKs, can prevent the phosphorylation and inactivation of PSP, maintaining its functional state. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which could phosphorylate PSP directly or influence its activity indirectly through other substrates, leading to PSP inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can inhibit the PI3K-Akt signaling pathway, which may lead to the activation of kinases that phosphorylate and inactivate PSP, thereby LY294002 maintains PSP in a dephosphorylated, active state. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which can have downstream effects on PSP activity. Inhibition of mTOR can prevent the phosphorylation of PSP by kinases regulated by mTOR, thereby maintaining PSP's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and by inhibiting PI3K it can prevent the activation of downstream kinases that may lead to the inactivation of PSP through phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting this pathway, PD98059 can prevent the phosphorylation and subsequent inactivation of PSP. | ||||||